Norma A. Alcantar

Norma A. Alcantar

Auto-generated profile, based on publicly available information

Norma A. Alcantar

Department of Chemical and Biomedical Engineering , University of South Florida , Tampa , Florida 33620 , United States

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2016 in Environmental Science & Technology
Verified
Journal Article
Closed access
DFDawn I. Fox
Dawn I. Fox
DSDaniela M. Stebbins
Daniela M. Stebbins
NANorma A. Alcantar
Norma A. Alcantar

30 March 2020 in Cancer Nanotechnology
Verified
Journal Article
Open access
PDF file
MWMarzenna Wiranowska
Marzenna Wiranowska
RSRupin Singh
Rupin Singh
RFRana Falahat
Rana Falahat
EWEva Williams
Eva Williams
JJJoseph O. Johnson
Joseph O. Johnson
NANorma Alcantar
Norma Alcantar
Background: We previously described the properties of a targeted drug delivery system (DDS) in a cell-free system. Here, in this comparative cell-based study (normal and tumor cells), we provide a quantitative analysis of the extracellular diffusion and intracellular localization of this DDS. This DDS consists of fluorescence-labeled paclitaxel encapsulated in non-ionic surfactant vesicles/niosomes embedded in a thermo-sensitive cross-linked chitosan hydrogel with an affinity for the MUC1 mucin surface antigen overexpressed on tumor cells, and designed for a sustained and controlled, localized delivery of embedded drugs. We evaluated DDS in our novel in vitro model using MatTek’ glass-bottom culture plates and compared human cancer cell lines (OV2008 epithelial origin carcinoma and U373 glioma, both overexpressing MUC1) with human normal epithelial control cell lines (IMMC3 and IOSE-121 using differential contrast and confocal microscopy. Results: Tumor cells incubated in the presence of chitosan alone or DDS-containing chitosan–niosome–paclitaxel–BODIPY 564/570, showed a prominent granular accumulation on their surface when compared to the normal cells. Quantitation of gray value light intensity of the extracellular region of chitosan alone treated OV2008 and IOSE-121 controls done by analysis of multiple radial line segments, 4 µm each, using ImageJ software showed 2 times higher intensity around the OV2008 than around normal IOSE-121 controls (p < 0.05). In the DDS-treated OV2008 cells, extracellular fluorescence intensity measured at different diffusion distances outside of the cells, in three different zones showed the difference in means of fluorescence intensity in these zones (p < 0.05) with the highest level of fluorescence near the cell surface indicating a concentration gradient, most likely driven by the high affinity of chitosan to the MUC1 receptor. Also, as chitosan alone accumulated two times more along the edge of tumor cells compared to normal cells, we found intracellular fluorescence intensity quantified at time intervals to be also 2 times higher in OV2008 than in normal IMCC3 cells (p < 0.05). Conclusion: Based on the observation of the DDS preferentially targeting tumor cells, there is a potential implication for the localized delivery of therapeutic drug doses to solid tumors or post-surgical solid tumors cavities containing residual tumor cells.

1 November 2015 in Cellular Immunology
Verified
Journal Article
Closed access
RFRana Falahat
Rana Falahat
MWMarzenna Wiranowska
Marzenna Wiranowska
Nathan GallantNathan Gallant
Nathan Gallant
RTRyan Toomey
Ryan Toomey
RHRobert Hill
Robert Hill
NANorma Alcantar
Norma Alcantar

26 June 2012 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
EWEva Christabel Williams
Eva Christabel Williams
RTRyan Toomey
Ryan Toomey
NANorma Alcantar
Norma Alcantar

13 October 2019 in Langmuir
Verified
Journal Article
Closed access
FGFei Guo
Fei Guo
DSDaniela M. de Lima Stebbins
Daniela M. de Lima Stebbins
RTRyan G. Toomey
Ryan G. Toomey
NANorma A. Alcantar
Norma A. Alcantar